RECRUITING

Effects of Caffeine on Reinforcement Learning in Healthy Adults Using PET/MRI

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This research study aims to determine whether and how caffeine intake affects learning process through reward feedback compared to placebo. The data acquired from this study would improve our understanding on the consequence and mechanism of caffeine intake in the aspect of learning process. Participants will perform a reinforcement learning task (i.e. Probabilistic Selection Task) and a motor inhibition task (i.e. Go/NoGo task) in a brain scan. The scan will be done with the Siemens Biograph mMR positron emission tomography (PET)/ magnetic resonance imaging (MRI) 3 Tesla scanner. The PET allows us to see the changes in the "reward signals" - dopamine - in the brain using a radioactive dye called \[11C\]Raclopride. The MRI, on the other hand, enables us to take detailed pictures of the brain activities during cognitive tasks using a high-powered magnet. Reviewing these pictures will help us understand the influence of caffeine on reward signals and brain activities during the learning process.

Official Title

Measure Striatal Adenosine-dopamine Receptors Interactions: from Molecule to Behaviors

Quick Facts

Study Start:2023-05-17
Study Completion:2026-12-31
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06763172

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 45 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:Yes
Standard Ages:ADULT
Inclusion CriteriaExclusion Criteria
  1. * Age ≥ 18 and ≤ 45.
  2. * Habitual caffeine intake ≥ 100 mg and ≤ 450 mg daily.
  3. * Non-smokers.
  4. * Clinically healthy.
  5. * Have normal vision or corrected to normal vision.
  1. * Pregnant or lactating women.
  2. * Women using hormonal contraceptives.
  3. * BMI \< 18.5 or \> 29.9
  4. * Sleep disturbance or extreme chronotype.
  5. * Urine test positive on one of the following substances: benzoylecgonine, morphine, d-Methamphetamine, d-Amphetamine, Benzodiazepines, Secobarbital, Methadone, Buprenorphine Glucuronide, Nortriptyline, MDMA, Oxycodone, PCP, Propoxyphene, and Cannabis/THC
  6. * Diagnosis of depression, anxiety, psychosis, or neurologic disorders in the last 5 years.
  7. * Heart or cardiovascular diseases.
  8. * Diabetes or other metabolic diseases.
  9. * Under chronic medications, for instance, painkiller and steroid.
  10. * Allergy to lactose (main ingredient of blank control dose)
  11. * Incapable to operate the tasks or comprehend the study information in English.
  12. * Metallic foreign bodies such as cardiac pacemakers, perfusion pumps, aneurysm clips, metallic tattoos anywhere on the body, tattoos near the eye.
  13. * Pre-existing medical conditions including a likelihood of developing seizures or claustrophobic reactions
  14. * Inability to lie flat on scanner bed for about 90 min as assessed by physical examination and medical history (e.g. arthritis)
  15. * Recent exposure to radiation (i.e., PET from other research studies) that, when combined with this study, would be above the allowable limits
  16. * Pregnancy or breastfeeding: A negative serum or urine pregnancy test is required on the day of the PET procedure
  17. * Body weight of \> 300 lbs (weight limit of the MRI scanner table)

Contacts and Locations

Study Contact

Hsiao-Ying Wey, PhD
CONTACT
6177241384
hsiaoying.wey@mgh.harvard.edu

Study Locations (Sites)

Athinoula A. Martinos Center for Biomedical Imaging
Charlestown, Massachusetts, 02129
United States

Collaborators and Investigators

Sponsor: Hsiao-Ying Wey

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2023-05-17
Study Completion Date2026-12-31

Study Record Updates

Study Start Date2023-05-17
Study Completion Date2026-12-31

Terms related to this study

Keywords Provided by Researchers

  • PET/fMRI

Additional Relevant MeSH Terms

  • Healthy
  • Caffeine
  • Adenosine
  • Dopamine D2/3 Receptor Availability